Abstract:Abstract The receptor tyrosine kinase AXL was first isolated in 1988 in a screen for transforming genes in CML and later characterized in 1991 as an overexpressed, transforming cDNA in AML. AXL has been identified as a promising therapeutic target based on diverse functions in cancer cells and immune cells. AXL has an amino acid sequence within its intracellular tyrosine kinase domain that shares close homology to RET, FGFR, EGFR, and PDGFR. The main ligand of AXL is GAS6. AXL is frequently overexpressed in many tumor types, even though genetic mutation and amplification events are relatively rare. This suggests a significant role for post-transcriptional regulation of AXL expression. We found that AXL was highly expressed in 60% of high-grade serous ovarian and FT primary tumors and in over 50% of metastatic omentum and peritoneal tumors. We initially identified AXL as a critical mediator of metastasis (Rankin 2010) and subsequently demonstrated that therapeutic inhibition of AXL improved sensitivity to platinum and taxane in ovarian cancer (Quinn 2018). We identified that 41% of chemoresistant tumors had high AXL expression at baseline. We also found that genetic and therapeutic inhibition of AXL through a tyrosine kinase inhibitor led to improved sensitivity to paclitaxel and carboplatin in preclinical models through increased uptake of paclitaxel in AXL inhibitor treated tumor cells. A novel engineered Axl decoy receptor was developed to bind Gas6 with femtomolar affinity by 80-fold (Kariolis 2014). These preclinical findings led to a Phase 1b trial of AVB-500 (a high affinity soluble decoy AXL receptor) every 2 weeks in combination with weekly paclitaxel (n=23) or pegylated liposomal doxorubicin (n=30) q28 days in platinum-resistant, recurrent ovarian cancer (Dec 2018-April 2020). PK was measured by serum AVB-500 levels, and PD determined by serum GAS6 levels. There was an objective response rate (ORR) of 34.8% including 2 complete responses. AVB-500 dose levels completely suppressed GAS6 to below the level of quantitation on C1D15. An exploratory, exposure-response analysis was conducted using the 10mg/kg cohort. This identified that a higher AVB-500 trough level at C1D15 was associated with longer PFS, which defined a model-based, minimally efficacious concentration (MEC) of AVB-500 of 13.8mg/L. Higher clinical activity was seen in patients who had a C1D15 above the MEC. This Phase 1b trial was performed using a model-informed drug development (MIDD) approach to inform the RP2D. Based on these results, GOG 3059/ENGOT OV-66: AXLerate-OC Phase 3, international, randomized, double blinded, placebo-controlled trial in platinum-resistant ovarian cancer comparing weekly paclitaxel vs weekly paclitaxel + batiraxcept (formerly AVB-500) was initiated. There were 366 patients enrolled between 4/2021-12/2022. Topline data was announced on 8/2/2023 that the median PFS in batiraxcept plus paclitaxel arm was 5.1 months compared to 5.5 months in the paclitaxel arm with no statistically significant difference. Further translational work is ongoing. Citation Format: Katherine Fuh. Targeting AXL in platinum-resistant ovarian cancer: from the lab bench to Phase 3 trial [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr IA012.

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).

Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo Plus Paclitaxel with Optional Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer

ENGOT-ov65/KEYNOTE-B96: Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo Plus Paclitaxel with Optional Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer.

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.

PR072/#1519 Effort: Clinical and Molecular Features Associated with Clinical Benefit from Adavosertib with or Without Olaparib in Recurrent Ovarian Cancer Following Progression on PARP Inhibition (NCT03579316)

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

A Phase I Study of TAK-659 and Paclitaxel in Patients with Taxane-Refractory Advanced Solid Tumors.

Abstract IA012: Targeting AXL in platinum-resistant ovarian cancer: from the lab bench to Phase 3 trial

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14

Data from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive &Lt;i>tp53</i>-Mutant Ovarian Cancer

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

Trabectedin Plus Pegylated Liposomal Doxorubicin in Relapsed Ovarian Cancer: Outcomes in the Partially Platinum-Sensitive (Platinum-Free Interval 6–12 Months) Subpopulation of OVA-301 Phase III Randomized Trial

Randomized, Double-Blind, Phase Iii Trial of Pazopanib Versus Placebo in Women Who Have Not Progressed after First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (aeoc): Results of an International Intergroup Trial (Ago-Ovar16).

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.